Sun Pharma - Public Comps and Valuation Multiples

Sun Pharma Overview

About Sun Pharma

Sun Pharmaceuticals Industries Ltd is India's generic pharmaceutical manufacturing company. The company’s substantial markets are the U.S. and India to make up the majority of revenue. The remaining is spread across both emerging and developed markets. In addition to generics, the company also produces and distributes name-brand formulas to specific geographies. It maintains manufacturing and research and development facilities globally to serve its markets but is majorly based in India.

Founded

1993

HQ

Employees

19.3K+

Website

sunpharma.com

Sectors

Biopharmaceuticals
Drug Development & Therapeutics
BioTech

Financials

LTM Revenue $6.2B

LTM EBITDA $1.8B

EV

$42.2B

Valuation Multiples

Multiples.vc

Valuation Multiples for 15K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Browse Valuation Multiples

Sun Pharma Financials

As of September 2025, Sun Pharma reported last 12-month revenue of $6.2B and EBITDA of $1.8B.

In the same period, Sun Pharma generated $4.9B in LTM gross profit and $1.3B in net income.

See Sun Pharma valuation multiples based on analyst estimates

Sun Pharma P&L

In the most recent fiscal year, Sun Pharma reported revenue of $5.9B and EBITDA of $1.9B.

Sun Pharma expects next 12-month revenue of XXX and NTM EBITDA of XXX

See Sun Pharma valuation multiples based on analyst estimates

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue	$6.2B	XXX	$5.9B	XXX	XXX	XXX
Gross Profit	$4.9B	XXX	$4.5B	XXX	XXX	XXX
Gross Margin	79%	XXX	77%	XXX	XXX	XXX
EBITDA	$1.8B	XXX	$1.9B	XXX	XXX	XXX
EBITDA Margin	28%	XXX	32%	XXX	XXX	XXX
EBIT	$1.5B	XXX	$1.4B	XXX	XXX	XXX
EBIT Margin	24%	XXX	24%	XXX	XXX	XXX
Net Profit	$1.3B	XXX	$1.2B	XXX	XXX	XXX
Net Margin	21%	XXX	21%	XXX	XXX	XXX
Net Debt	XXX	XXX	n/a	XXX	XXX	XXX

Financial data powered by Morningstar, Inc.

.seo-only-financials-wrapper { position: static; left: auto; width: auto; height: auto; overflow: visible; }

Financial performance metrics for Sun Pharma including revenue, profitability, and margin analysis across different time periods. The company reported last twelve months revenue of $6.2B. EBITDA for the last twelve months was $1.8B. In the most recent fiscal year, Sun Pharma achieved $5.9B in revenue and $1.9B in EBITDA.
Financial Metric	Last Twelve Months (LTM)	Next Twelve Months (NTM)	Most Recent Fiscal Year	Current Fiscal Year (2025)	Next Fiscal Year (2026)	Two Years Forward (2027)
Total Revenue	$6.2B	Analyst estimates available to subscribers	$5.9B	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit	$4.9B	Analyst estimates available to subscribers	$4.5B	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit Margin	79.4% gross margin	Analyst estimates available to subscribers	76.6% gross profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA (Earnings Before Interest, Taxes, Depreciation, Amortization)	$1.8B	Analyst estimates available to subscribers	$1.9B	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA Margin	28.4% EBITDA margin	Analyst estimates available to subscribers	31.8% EBITDA margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT (Earnings Before Interest and Taxes)	$1.5B	Analyst estimates available to subscribers	$1.4B	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT Margin	23.9% EBIT margin	Analyst estimates available to subscribers	24.2% EBIT margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Income (Net Profit)	$1.3B	Analyst estimates available to subscribers	$1.2B	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Profit Margin	21.1% net profit margin	Analyst estimates available to subscribers	21.0% net profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Debt Position	Detailed debt information available to subscribers	Detailed debt information available to subscribers	n/a	Detailed debt information available to subscribers	Detailed debt information available to subscribers	Detailed debt information available to subscribers

Financial Performance Summary for Sun Pharma

This financial data table provides comprehensive performance metrics for Sun Pharma, a company based in India. The metrics include revenue, profitability measures, and operational efficiency indicators across multiple time periods.

Recent Performance Highlights

Sun Pharma generated $6.2B in revenue over the last twelve months.
The company achieved $1.8B in EBITDA over the last twelve months.
Gross profit for the last twelve months was $4.9B.
Net income over the last twelve months reached $1.3B.

Fiscal Year Performance

In the most recent fiscal year, Sun Pharma reported $5.9B in total revenue.
Fiscal year EBITDA was $1.9B.
The company maintained a gross profit margin of 76.6% in the most recent fiscal year.
EBITDA margin for the fiscal year was 31.8%.
Net profit margin reached 21.0% in the most recent fiscal year.

This financial data is sourced from Morningstar, Inc. and represents the most recent available information for Sun Pharma. Forward-looking estimates and detailed financial projections are available through our premium subscription service.

Sun Pharma Stock Performance

Sun Pharma has current market cap of INR 3.98T (or $44.9B), and EV of INR 3.74T (or $42.2B).

Market Cap Evolution

Sun Pharma Stock Data

As of October 17, 2025, Sun Pharma's stock price is INR 1659 (or $19).

See Sun Pharma trading valuation data

EV	Market Cap	Price 1D	Price 1M	Price 3M	Price 12M	EPS
$42.2B	$44.9B	XXX	XXX	XXX	XXX	$0.54

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Start Free Trial

Sun Pharma Valuation Multiples

Sun Pharma's trades at 7.3x EV/Revenue multiple, and 23.5x EV/EBITDA.

See valuation multiples for Sun Pharma and 15K+ public comps

Sun Pharma Financial Valuation Multiples

As of October 17, 2025, Sun Pharma has market cap of $44.9B and EV of $42.2B.

Equity research analysts estimate Sun Pharma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Sun Pharma has a P/E ratio of 34.3x.

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Market cap (current)	$44.9B	XXX	$44.9B	XXX	XXX	XXX
EV (current)	$42.2B	XXX	$42.2B	XXX	XXX	XXX
EV/Revenue	6.8x	XXX	7.3x	XXX	XXX	XXX
EV/EBITDA	24.0x	XXX	23.5x	XXX	XXX	XXX
EV/EBIT	28.4x	XXX	31.0x	XXX	XXX	XXX
EV/Gross Profit	8.6x	XXX	n/a	XXX	XXX	XXX
P/E	34.3x	XXX	37.6x	XXX	XXX	XXX
EV/FCF	39.2x	XXX	32.7x	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Sun Pharma Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Start Free Trial

Sun Pharma Margins & Growth Rates

Sun Pharma's last 12 month revenue growth is 10%

Sun Pharma's revenue per employee in the last FY averaged $0.3M, while opex per employee averaged $0.2M for the same period.

Sun Pharma's rule of 40 is 41% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Sun Pharma's rule of X is 53% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

See operational valuation multiples for Sun Pharma and other 15K+ public comps

Sun Pharma Operational Valuation Multiples

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue Growth	10%	XXX	10%	XXX	XXX	XXX
EBITDA Margin	28%	XXX	31%	XXX	XXX	XXX
EBITDA Growth	11%	XXX	6%	XXX	XXX	XXX
Rule of 40	41%	XXX	41%	XXX	XXX	XXX
Bessemer Rule of X	XXX	XXX	53%	XXX	XXX	XXX
Revenue per Employee	XXX	XXX	$0.3M	XXX	XXX	XXX
Opex per Employee	XXX	XXX	$0.2M	XXX	XXX	XXX
S&M Expenses to Revenue	XXX	XXX	13%	XXX	XXX	XXX
G&A Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
R&D Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
Opex to Revenue	XXX	XXX	52%	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics

Pharma Analytics

Private Equity

ERP Software

Developer Tools

Consumer SaaS

Streaming Platforms

Explore Valuation Multiples by Industry

Start Free Trial